Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company has operations in pharmaceutical, animal health, and consumer care.
Website: merck.com


  • Pretty weak financial results growth rate 3.4% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (17.5%)
  • Dividend yield for the last twelve months 4.0%
  • Free cash flow yield 2.2% (LTM)
  • Share price is 4.4% higher than minimum and 40.0% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (9.2x vs
    )
  • For the last 3 months insiders bought company shares on $0.1 mln (0.000% of cap.)

Key Financials (Download financials)

Ticker: MRK
Share price, USD:  (+1.1%)79.84
year average price 107.54  


year start price 131.20 2024-04-26

max close price 132.96 2024-06-24

min close price 76.46 2025-04-16

current price 79.84 2025-04-25
Common stocks: 2 528 810 012

Dividend Yield:  4.0%
FCF Yield LTM: 2.2%
EV / LTM EBITDA: 9.2x
EV / EBITDA annualized: 10.5x
Target EV / EBITDA (hist percentile):
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 201 900
Net Debt ($m): 23 481
EV (Enterprise Value): 225 381
EBITDA LTM ($m): 24 435
EV / LTM EBITDA: 9.2x
Price to Book: 4.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-04-22zacks.com

Merck Q1 Earnings Coming Up: Should You Buy the Stock Now?

2025-04-21seekingalpha.com

Merck: Now A Single-Digit P/E With Double-Digit EPS Growth, Technical Support

2025-04-21seekingalpha.com

Merck & Co.: Pipeline Resilience To Unlock Value

2025-04-17globenewswire.com

MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

2025-04-14accessnewswire.com

Levi & Korsinsky Reminds Merck Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - MRK

2025-04-14accessnewswire.com

MRK DEADLINE TODAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action - MRK

2025-04-14accessnewswire.com

MRK LAWSUIT ALERT: Levi & Korsinsky Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

2025-04-14accessnewswire.com

Levi & Korsinsky Notifies Shareholders of Merck & Co., Inc. (MRK) of a Class Action Lawsuit and an Upcoming Deadline

2025-04-13prnewswire.com

MRK Investors Have Final Opportunity Today to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm

2025-04-13prnewswire.com

MRK Deadline Tomorrow: MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data